XENCOR INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
XENCOR INC. - More news...
XENCOR INC. - More news...
- Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
- Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
- Xencor Reports First Quarter 2022 Financial Results
- Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022
- Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
- Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
- Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
- Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022
- Xencor to Present at Upcoming Investor Conferences
- Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones
- Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
- Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
- Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
- Xencor to Present at Upcoming Investor Conferences
- Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
- Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting
- Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306
- Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting
- Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
- Xencor to Present at Upcoming Investor Conferences
- Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021
- Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
- Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting
- Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference
- Xencor Reports Second Quarter 2021 Financial Results
- Xencor to Present at Upcoming Investor Conferences
- Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021
- Xencor to Present at the Jefferies Virtual Healthcare Conference
- Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19
- Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
